argenx SE (ARGX)
| Market Cap | 60.62B +11.6% |
| Revenue (ttm) | 5.92B +60.6% |
| Net Income | 1.88B +22.4% |
| EPS | 27.79 +24.1% |
| Shares Out | 62.74M |
| PE Ratio | 34.54 |
| Forward PE | 27.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 225,890 |
| Open | 975.62 |
| Previous Close | 981.33 |
| Day's Range | 959.27 - 976.85 |
| 52-Week Range | 661.85 - 1,072.75 |
| Beta | -0.06 |
| Analysts | Buy |
| Price Target | 1,147.35 (+19.51%) |
| Earnings Date | Oct 22, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,147.35, which is an increase of 19.51% from the latest price.
News
Argenx price target lowered to $1,130 from $1,190 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Argenx (ARGX) to $1,130 from $1,190 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets among its…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...
Roth Capital biotech analysts hold analyst/industry conference call
Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthus’ (DNTH) and Argenx’s (ARGX) December MMN results on an Analyst/Industry conference call ...
argenx SE Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
BD is focused mainly on earlier-stage, multi-indication assets to build growth beyond VYVGART, including UNP and Forte. VYVGART momentum, potential 2027 launches and rising investment are expected to support continued margin expansion.
argenx SE Announces Agreement to Acquire Unnatural Products, Inc. for Up to Approximately $1.15 billion
argenx SE has announced a definitive agreement to acquire Unnatural Products, Inc., adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds...
Argenx to acquire Unnatural Products for $1.15B
Argenx (ARGX) announced a definitive agreement to acquire Unnatural Products, adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. Argenx, which already holds a min...
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Here's why Argenx could keep winning.
Argenx To Acquire Unnatural Products In Deal Worth Up To $1.15 Billion
(RTTNews) - argenx (ARGX) has agreed to acquire private biotechnology company Unnatural Products (UNP) in a transaction valued at up to $1.15 billion, expanding its capabilities in the development of ...
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc...
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
Argenx announces Phase 3 ALKIVIA study met primary, secondary endpoints
argenx (ARGX) announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART Hytrulo in patients with autoimmune myositis will be featured in a late-brea...
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an au...
Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
argenx to Present at Upcoming Investor Conferences
November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following...
Argenx price target lowered to $1,232 from $1,301 at Citi
Citi lowered the firm’s price target on Argenx (ARGX) to $1,232 from $1,301 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3…
Argenx price target raised to $1,190 from $1,140 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Argenx (ARGX) to $1,190 from $1,140 and keeps an Overweight rating on the shares.
Argenx price target lowered to $1,120 from $1,185 at Guggenheim
Guggenheim lowered the firm’s price target on Argenx (ARGX) to $1,120 from $1,185 and keeps a Buy rating on the shares despite the company having delivered what the firm calls…
argenx: 3 Key Takeaways for Long-Term Investors
Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.
Argenx price target raised to $861 from $823 at Baird
Baird analyst Collen Kusy raised the firm’s price target on Argenx (ARGX) to $861 from $823 and keeps a Neutral rating on the shares. The firm updated its model following…
Argenx price target lowered to $1,336 from $1,356 at Wells Fargo
Wells Fargo lowered the firm’s price target on Argenx (ARGX) to $1,336 from $1,356 and keeps an Overweight rating on the shares. The firm notes that the muted reaction reflects…
argenx (ARGX) Q3 2026 Earnings Call Transcript
VYVGART revenue surged 54% year-over-year amid strategic Forte Biosciences acquisition.
argenx SE Reports Third Quarter 2026 Financial Results and Business Update
argenx SE reported its third quarter 2026 financial results, highlighted by global product net sales of $1.7 billion for VYVGART, representing 54% year-over-year growth and 13% quarter-over-quarter gr...
What argenex (ARGX) Said on Its Q3 Earnings Call
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chro...
Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.
Argenx Q3 Net Income Rises As VYVGART Sales Increase
(RTTNews) - Argenx SE (ARGX) reported on Thursday higher third-quarter net income and product sales, reflecting continued growth of its VYVGART franchise.